PMC:7736111 / 103535-104306 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2413","span":{"begin":108,"end":116},"obj":"Species"},{"id":"2414","span":{"begin":343,"end":353},"obj":"Species"},{"id":"2415","span":{"begin":603,"end":613},"obj":"Species"},{"id":"2416","span":{"begin":243,"end":250},"obj":"Chemical"},{"id":"2417","span":{"begin":99,"end":107},"obj":"Disease"}],"attributes":[{"id":"A2413","pred":"tao:has_database_id","subj":"2413","obj":"Tax:9606"},{"id":"A2414","pred":"tao:has_database_id","subj":"2414","obj":"Tax:2697049"},{"id":"A2415","pred":"tao:has_database_id","subj":"2415","obj":"Tax:2697049"},{"id":"A2417","pred":"tao:has_database_id","subj":"2417","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In an elegant recent study, Cao et al. (2020) performed sc-RNA-seq of B cells from 60 convalescent COVID-19 patients. The study led to the identification of 14 neutralizing antibodies, among which one (BD-368-2) showed the most potent effect. BD-368-2 was further explored for its efficacy in animal models and showed therapeutic potential in SARS-CoV-2 transgenic animals. Further, the study suggested the use of two different monoclonal antibodies targeting different epitopes as a more viable therapeutic intervention than a single antibody, which is impressive considering the emerging mutations in SARS-CoV-2. Thus, more research in this direction is needed to find antibodies with potent neutralization property for targeted therapy to alleviate the disease burden."}

{"project":"LitCovid-sentences","denotations":[{"id":"T611","span":{"begin":0,"end":117},"obj":"Sentence"},{"id":"T612","span":{"begin":118,"end":242},"obj":"Sentence"},{"id":"T613","span":{"begin":243,"end":373},"obj":"Sentence"},{"id":"T614","span":{"begin":374,"end":614},"obj":"Sentence"},{"id":"T615","span":{"begin":615,"end":771},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In an elegant recent study, Cao et al. (2020) performed sc-RNA-seq of B cells from 60 convalescent COVID-19 patients. The study led to the identification of 14 neutralizing antibodies, among which one (BD-368-2) showed the most potent effect. BD-368-2 was further explored for its efficacy in animal models and showed therapeutic potential in SARS-CoV-2 transgenic animals. Further, the study suggested the use of two different monoclonal antibodies targeting different epitopes as a more viable therapeutic intervention than a single antibody, which is impressive considering the emerging mutations in SARS-CoV-2. Thus, more research in this direction is needed to find antibodies with potent neutralization property for targeted therapy to alleviate the disease burden."}